ࡱ>  l \pThe Free Software Foundation B=PF0*8X@"1 Helvetica1Courier1 Courier New1 Courier New1 Helvetica$#,##0_);($#,##0)$#,##0_);[Red]($#,##0)$#,##0.00_);($#,##0.00)$#,##0.00_);[Red]($#,##0.00)-**_($* #,##0_);_($* (#,##0);_($* "-"_);_(@_)*)'_(* #,##0_);_(* (#,##0);_(* "-"_);_(@_)5,2_($* #,##0.00_);_($* (#,##0.00);_($* "-"??_);_(@_)2+/_(* #,##0.00_);_(* (#,##0.00);_(* "-"??_);_(@_)2$#,##0.00;[Red]$#,##0.003$#,##0.00;[Red]($#,##0.00)4$#,##0;[Red]($#,##00)50.00%;[Red](0.00%)6 0%;[Red](0%)7#,##0.00;[Red](#,##0.00)8#,##0;[Red](#,##0)                + ) , *   Ј ~~ ؈ ~~#؈ ~~ ؈ ~~8#܈ ~~9#܈ ~~4#܈ ~~3#܈ ~~7#܈ ~~83ffff̙̙3f3fff3f3f33333f33 ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS[, Balance Sheet'IIncome Statement `Income Statement (1)k Cash Flows&Recently Adopted Accounting Sta&Recently Adopted Accounting (1)&x2 Fair Value of Financial Instr&2 Fair Value of Financial I (1)&2 Fair Value of Financial I (2)&2 Fair Value of Financial I (3)&2 Fair Value of Financial I (4)&4 Property and Equipment and As&o6 Notes Payable and Gain on Ear&82014 Stock Incentive Plan and 2&2014 Stock Incentive Plan a (1)&$Valuation Assumptions for StockE3 9 Warrants(A9 Warrants (1)GJ9 Warrants (2)X12 Net Loss Per Share c12 Net Loss Per Share (1)&nComparison of the Three Months &Research and Development ExpensCash Flows (1)Item 6 Exhibits%Subsidiaries of the Registrant l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three Months !Research and Development ExpensCash Flows (1)Item 6 Exhibits Subsidiaries of the RegistrantU } 0}       ARGOS THERAPEUTICS INC 10-Q 05/15/2018 ARGOS THERAPEUTICS, INC.Delaware 56-2110007' (State or other jurisdiction of (I.R.S. Employer& incorporation or organization) Identification No.)   4233 Technology Drive~  Durham, North Carolina0((Address of principal executive offices) (Zip Code)$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,B||pd:cA=PF0*8X> @ l  J  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INCTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three Months !Research and Development ExpensCash Flows (1)Item 6 Exhibits Subsidiaries of the RegistrantU } U} 8} } $      ARGOS THERAPEUTICS INC 10-Q 05/15/2018 No changesLarge accelerated filer ?Accelerated filer ? Non-accelerated filer7 /? (Do not check if a smaller reporting company)! Smaller reporting company ?   Emerging growth company ?  $ ____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/$,~rB6*=PF0*8X> @  l  %*+  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changes Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three Months !Research and Development ExpensCash Flows (1)Item 6 Exhibits Subsidiaries of the RegistrantU } y } $ } :}  %     ARGOS THERAPEUTICS INC 10-Q 05/15/2018TABLE OF CONTENTS%PART I. FINANCIAL INFORMATION Item 1.  Financial Statements~   - %Condensed Consolidated Balance Sheets~     (unaudited)  , $Condensed Consolidated Statements of~    Operations (unaudited),$Condensed Consolidated Statements of~ &Comprehensive Loss (unaudited),$Condensed Consolidated Statements of~ Cash Flows (unaudited)1)Notes to Condensed Consolidated Financial~ Statements (unaudited)Item 2.,$Management?s Discussion and Analysis~ 80of Financial Condition and Results of OperationsItem 3.0(Quantitative and Qualitative Disclosures~ About Market RiskItem 4.Controls and Procedures~ "PART II. OTHER INFORMATIONItem 1.Legal Proceedings~ Item 1A. Risk Factors~ Item 6.Exhibits~ v Signatures~ zD( lwkBoG\"qY !"#$ !$"____________________________1#)Created by Morningstar Document Research.0$(http://documentresearch.morningstar.com/ P=PF0*8X> @2$$##"" l  5U?;~ "=Accrued expenses~ #M~   Notes payable~ /~ 6/2*Current portion of other convertible notes~ n~ B!Total current liabilities~ RG~ B1)Convertible note payable to related party~ ~ G.&Long-term portion of other convertible~ c~ T notesDeferred liabilities~ r~ Warrants~ R; ~ !DFl{ol~yr}vG6 ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4   Commitments   -    - !Stockholders? deficit!!!!!!!!3"+Preferred stock $0.001 par value; 5,000,000"" "-""" "-"1#)shares authorized as of December 31, 2017;$3and March 31, 2018; 0 shares issued and outstanding2%*as of December 31, 2017 and March 31, 20182&*Common stock $0.001 par value; 200,000,000&&~ &N\&&&~ &Ɵ&1')shares authorized as of December 31, 20174(,and March 31, 2018; 5,906,620 and 10,224,7784),shares issued and outstanding as of December#*31, 2017 and March 31, 2018,+$Accumulated other comprehensive loss++~ +bQ+++~ +#+",Additional paid-in capital,,~ ,r=V,,,~ ,X,-Accumulated deficit--~ -fz,---~ -ҝ-#.Total stockholders? deficit..~ .e...~ .^=.3/+Total liabilities and stockholders? deficit/~ /,//~ /"H/01$2____________________________13)Created by Morningstar Document Research.04(http://documentresearch.morningstar.com/.m8)]?1n=PF0*8X> @z443322////     l  )[H_  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three Months !Research and Development ExpensCash Flows (1)Item 6 Exhibits Subsidiaries of the RegistrantU } $4} $ } y} $ } y} $ )                                 ARGOS THERAPEUTICS INC 10-Q 05/15/2018Income StatementThree Months Ended    March 31,  ~  ~       Revenue ~ l  ~ j          Operating expenses Research and development~ ~ qR"General and administrative~ .~ ꆘ,$Impairment of property and equipment~ k| -Restructuring costs~ 1 - Total operating expenses~ F ~ Operating loss~ jl~ %Other income (expense)Interest income~ ~ Interest expense~ >~ ,$Gain on early extinguishment of debt~ 9 -1)Change in fair value of warrant liability~ .~   Other expense~ ^~ ^#Other income (expense), net~ Vؾ~ Net loss~ DB~ n#D lxl6 .D2)* ! " # $ % & ' (          -!%Net loss per share, basic and diluted!!RQ'!!!Qѿ!"""""""""3#+Weighted average common shares outstanding,##~ #2~###~ ##$basic and diluted%$&____________________________1')Created by Morningstar Document Research.0((http://documentresearch.morningstar.com/f=PF0*8X> @j ((''&&!!!!      l  k  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome Statement Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three Months !Research and Development ExpensCash Flows (1)Item 6 Exhibits Subsidiaries of the RegistrantU } 0} $ }  } $ }  } $                        ARGOS THERAPEUTICS INC 10-Q 05/15/2018Income StatementThree Months Ended    March 31,  ~  ~  Net loss ~ DB  ~ n#           Other comprehensive gain        0(Foreign currency translation gain (loss)~ ~  Total comprehensive loss~ rYB~ &~$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0\xl6 iyu=PF0*8X> @Z       l  I  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1)!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three Months !Research and Development ExpensCash Flows (1)Item 6 Exhibits Subsidiaries of the RegistrantU } :} $ }  } $ }  } $ I                                 ARGOS THERAPEUTICS INC 10-Q 05/15/2018 Cash FlowsThree Months Ended    March 31,  ~  ~ , $Cash flows from operating activities         Net loss ~ DB  ~ n# 0 (Adjustments to reconcile net loss to net        )!cash used in operating activities%Depreciation and amortization~ >~ >z ( Share-based compensation expense~ ޢ~ Z+,$Gain on early extinguishment of debt~ : -1)Impairment loss on property and equipment~ k| -3+Decrease in fair value of warrant liability~ |%~ J%Loss on disposal of equipment~ ~ *"Interest accrued on long-term debt~ m~ & 4,Changes in operating assets and liabilities:.&Prepaid expenses and other receivables~ ~ RAccounts payable~ ~ ZAccrued expenses~ =~ d3+Current portion of restructuring obligation~ 6" -&Long-term deferred liabilities~ RR~ D3+Long-term portion of manufacturing research~  -"and development obligation-%Net cash used in operating activities~ ~ D{l~r<?Kn;nT, ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ?          ,!$Cash flows from investing activities!!!!!!!!*""Purchase of property and equipment""~ "'""" "-"4#,Proceeds from sale of property and equipment##~ #&Y###~ #¦#$$$$$$$$$0%(Net cash (used in) provided by investing%%~ % %%%~ %¦%& activities''''''''',($Cash flows from financing activities((((((((2)*Net proceeds from sale of common stock and)) )-)))~ )j)*warrants-+%Proceeds from employee stock purchase++~ +Ƃ+++ +-+ ,plan,-$Payment on capital lease obligations--~ -Z--- ---!.Payments on notes payable..~ .\...~ . ./////////00(Net cash (used in) provided by financing00~ 0\[000~ 0&01 activities02(Effect of exchange rates changes on cash22~ 2v222~ 2n203(Net (decrease) increase in cash and cash33~ 3ln333~ 36o34 equivalents-5%Cash, cash equivalents and restricted55555555 6cash7Beginning of period77~ 7g 777~ 7 78888888889 End of period9~ 9~<99~ 9Ι9:::::::::8;0Supplemental disclosure of cash flow information;;;;;;;;<Cash paid for interest<~ <<<~ <~<4=,Supplemental disclosure of noncash investing======== >and financing activities2?*Issuance of warrants in exchange for early?~ ?P?? ?$-?D6lskQ(pTP: bRc@ A B C D E F G H @extinguishment of debt4A,Purchases of property and equipment includedA~ AZAA A$-A0B(in accounts payable and accrued expenses/C'Sale of property and equipment includedC C$-CC~ COCDin other receivablesE$F____________________________1G)Created by Morningstar Document Research.0H(http://documentresearch.morningstar.com/Z&{S=PF0*8X> @HHGGFFCCCCAAAA????<<<<9999      l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three Months !Research and Development ExpensCash Flows (1)Item 6 Exhibits Subsidiaries of the RegistrantU } U5} $ } y} $      ARGOS THERAPEUTICS INC 10-Q 05/15/2018-%Recently Adopted Accounting Standards!Cash and cash equivalents~ ̧2 *Restricted cash included in current assets  ~ b 4 ,Total cash, cash equivalents, and restricted ~ ~< 0 (cash shown in the Condensed Consolidated Statement of Cash Flows$ ____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/$,{ocW F=PF0*8X> @*   l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three Months !Research and Development ExpensCash Flows (1)Item 6 Exhibits Subsidiaries of the RegistrantU } U5} $ }  } $      ARGOS THERAPEUTICS INC 10-Q 05/15/2018-%Recently Adopted Accounting Standards!Cash and cash equivalents~ = 2 *Restricted cash included in current assets  ~ *- 4 ,Total cash, cash equivalents, and restricted ~ g  0 (cash shown in the Condensed Consolidated Statement of Cash Flows$ ____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/$,{ocW F=PF0*8X> @*   l  &  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three Months !Research and Development ExpensCash Flows (1)Item 6 Exhibits Subsidiaries of the RegistrantU } %} $      ARGOS THERAPEUTICS INC 10-Q 05/15/2018.&2. Fair Value of Financial Instruments Quoted Prices Significant   Significant  Balance as of    in Active  Other   Unobservable   December 31,    Markets for   Observable  Inputs ~   " Identical Assets (Level 1)  Inputs   (Level 3)        (Level 2) Assets                Money-market funds~  $-   $-  ~ "Total assets at fair value~  $-   $-  ~  Liabilities     Warrants $- $- ~  R;   ~ R; 'Total liabilities at fair value $- $- ~  R;   ~ R; $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/4P znbV("=9-!=PF0*8X> @#               l  I  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three Months !Research and Development ExpensCash Flows (1)Item 6 Exhibits Subsidiaries of the RegistrantU } %} $      ARGOS THERAPEUTICS INC 10-Q 05/15/2018.&2. Fair Value of Financial Instruments Quoted Prices Significant   Significant  Balance as of    in Active  Other   Unobservable   March 31,    Markets for   Observable  Inputs ~    Identical Assets  Inputs   (Level 3)    (Level 1)   (Level 2) Assets                Money-market funds~  $-   $-  ~ "Total assets at fair value~  $-   $-  ~  Liabilities     Warrants $- $- ~  !  ~ !'Total liabilities at fair value $- $- ~  !  ~ !$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/44 znbV+/YUI==PF0*8X> @"$                l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three Months !Research and Development ExpensCash Flows (1)Item 6 Exhibits Subsidiaries of the RegistrantU } 0.} $ } I} $      ARGOS THERAPEUTICS INC 10-Q 05/15/2018.&2. Fair Value of Financial Instruments'Balance as of December 31, 2017~ R; . &Change in fair value during the period  ~ J $ Balance as of March 31, 2018 ~ !   $ ____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/$,znbVSG;=PF0*8X> @*   l  h  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three Months !Research and Development ExpensCash Flows (1)Item 6 Exhibits Subsidiaries of the RegistrantU } a} $      ARGOS THERAPEUTICS INC 10-Q 05/15/2018.&2. Fair Value of Financial InstrumentsAs of December 31, 2017    Amortized  Gross  Gross   Aggregate   Cost   Unrealized   Unrealized  Fair   Basis  Holding  Holding  Value       Gains  Losses Money-market funds ~    $-   $-  ~  ~  $-   $-  ~ $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,|znbV Zv=PF0*8X> @               l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three Months !Research and Development ExpensCash Flows (1)Item 6 Exhibits Subsidiaries of the RegistrantU } a} $      ARGOS THERAPEUTICS INC 10-Q 05/15/2018.&2. Fair Value of Financial InstrumentsAs of March 31, 2018    Amortized  Gross  Gross   Aggregate   Cost   Unrealized   Unrealized  Fair   Basis  Holding  Holding  Value       Gains  Losses Money-market funds ~    $-   $-  ~  ~  $-   $-  ~ $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,|znbV]y=PF0*8X> @               l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three Months !Research and Development ExpensCash Flows (1)Item 6 Exhibits Subsidiaries of the RegistrantU } 8} $ }  } $ }  } $                            ARGOS THERAPEUTICS INC 10-Q 05/15/2018:24. Property and Equipment and Assets Held for Sale December 31, March 31,  ~  ~      & Office furniture and equipment ~  '  ~  '  Computer equipment  ~ F_<   ~ v;  Computer software  ~    ~  Laboratory equipment~ BMq~ BhLeasehold improvements~ *~ *+#Total property and equipment, gross~ q)~ 2 7/Less: Accumulated depreciation and amortization~ 4~ #Property and equipment, net~ Υ~ $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/84 nbVJ}\}qe==PF0*8X> @Z      l  #|  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three Months !Research and Development ExpensCash Flows (1)Item 6 Exhibits Subsidiaries of the RegistrantU } $4} $ } y} $ } y} $ #                                 ARGOS THERAPEUTICS INC 10-Q 05/15/2018A96. Notes Payable and Gain on Early Extinguishment of Debt December 31, March 31,  ~  ~ 2 *Convertible note payable to Pharmstandard, ~   ~ G " including accrued interest- %Convertible note payable to Invetech,  ~ ^d   ~ bX " including accrued interest1)Convertible note payable to Saint-Gobain,~ F~ ~"including accrued interest2*Note payable to Medinet, including accrued~ .~ (/interestOther notes payable~ ~ ~ Total debt~ ~ ⟏0(Less current portion of convertible note~ ~ ¶.&payable to Invetech, including accruedinterest0(Less current portion of convertible note~ ~ <2*payable to Saint-Gobain, including accruedinterest/'Less current portion of note payable to~ bV~ J+#Medinet, including accrued interest3+Less current portion of other notes payable~ '~ n.&Long-term portion of notes payable and~ ~ n!convertible notes payableDk lg[OC0 uO_Mo9%_F ! " $ ____________________________1!)Created by Morningstar Document Research.0"(http://documentresearch.morningstar.com/ (=PF0*8X> @Z ""!!      l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three Months !Research and Development ExpensCash Flows (1)Item 6 Exhibits Subsidiaries of the RegistrantU } 0.} $ }  } $ }  } $                       ARGOS THERAPEUTICS INC 10-Q 05/15/2018G?2014 Stock Incentive Plan and 2014 Employee Stock Purchase PlanThree Months Ended    March 31,  ~  ~  Research and development ~   ~ F " General and administrative  ~ -   ~   Restructuring costs  ~ R1    - .&Total stock-based compensation expense~ ޢ~ Z+$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.aUI=*4(=PF0*8X> @Z       l  a#  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three Months !Research and Development ExpensCash Flows (1)Item 6 Exhibits Subsidiaries of the RegistrantU } $4} $ }  }  $ } } $                             ARGOS THERAPEUTICS INC 10-Q 05/15/2018G?2014 Stock Incentive Plan and 2014 Employee Stock Purchase Plan Number ofWeighted  Weighted   Shares  Average Exercise  Average       Price   Contractual           Term            (in years)+ #Outstanding as of December 31, 2017  ~ *s    ףp=[@     Granted - $-     Exercised - $-     Cancelled~ :Q]@    ( Outstanding as of March 31, 2018~ b q= ף]@   \(\@     ( Exercisable as of March 31, 2018~ OR]@   q= ףp@     3+Vested and expected to vest as of March 31,~ / Gz]@   = ףp=@ ~ $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/: aUI=_[x;}#|=PF0*8X> @         l  `2  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1) 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three Months !Research and Development ExpensCash Flows (1)Item 6 Exhibits Subsidiaries of the RegistrantU } } $ }  } $} $ } $}  $ } } $} $ } $} $      ARGOS THERAPEUTICS INC 10-Q 05/15/2018UMValuation Assumptions for Stock Option Plans and Employee Stock Purchase PlanStock Option Plans  Employee Stock            Purchase Plan   Three Months Ended  Three Months Ended    March 31,   March 31,  ~  ~  ~  ~  Risk-free interest rate   )\(@ %   -    Gz? %   - Dividend yield~  % -  ~    %  - Expected term (in years)~  -   ?   - Volatility~ Z % -  ~    %  -$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0SG;/B -K]sg?=PF0*8X> @r          l  _@  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three Months !Research and Development ExpensCash Flows (1)Item 6 Exhibits Subsidiaries of the RegistrantU } m)} $ } I } $ }  }  $ }       ARGOS THERAPEUTICS INC 10-Q 05/15/2018 9. Warrants*"Type of Warrant and ClassificationDate of IssuanceNumber of Shares  Exercise Price  Expiration               Date(s) Common stock - Equity   9/29/14   ~ @   ffffff@   9/29/21 Common stock - Equity   3/4/16   ~ N0  ~    3/4/21 Common stock - Equity   6/29/16   ~ *   ~    6/29/21 Common stock - Liability   8/2/16   ~   ~    8/02/21Common stock - Equity3/6/17~ "N ~  j  3/06/22$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,W|}qP=PF0*8X> @Z   l  I  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three Months !Research and Development ExpensCash Flows (1)Item 6 Exhibits Subsidiaries of the RegistrantU } <(} $ } } $      ARGOS THERAPEUTICS INC 10-Q 05/15/2018 9. Warrants August 2016   Warrants Exercise price ~   Expiration date   August 2, 2021 ) !Total shares issuable on exercise  ~   $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/(T}qB}=PF0*8X> @2   l  X  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three Months !Research and Development ExpensCash Flows (1)Item 6 Exhibits Subsidiaries of the RegistrantU } :} $ } } $} $ } U} $                             ARGOS THERAPEUTICS INC 10-Q 05/15/2018 9. WarrantsDecember 31, 2017March 31, 2018     " Exercise price of warrants ~   ~  . &Closing underlying stock price on date ~    ?   of valuation' Expected stock price volatility  ~  %  ~  % Expected life (in years)p= ף @p= ף @Risk-free interest rateRQ@ %Q@ %Expected dividend yield~  %~  %-%Valuation per common share underlying\(\?? each warrant80Total liability for warrants on the consolidated~ R; ~ ! balance sheet0(Decrease in fair value during the period~ f~  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/:}qh=nU=PF0*8X> @r     l  b  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share (1)!Comparison of the Three Months !Research and Development ExpensCash Flows (1)Item 6 Exhibits Subsidiaries of the RegistrantU } -} $ } y} $ } y} $                       ARGOS THERAPEUTICS INC 10-Q 05/15/201812. Net Loss Per ShareThree Months Ended    March 31,  ~  ~       Net loss ~ DB  ~ n# , $Weighted average shares outstanding,  ~ 2~   ~  basic and diluted-%Net loss per share, basic and dilutedRQ'Qѿ$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.\~rf0'v=PF0*8X> @Z       l  _m  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share!Comparison of the Three Months !Research and Development ExpensCash Flows (1)Item 6 Exhibits Subsidiaries of the RegistrantU } y#} $ }  } $ }  } $                     ARGOS THERAPEUTICS INC 10-Q 05/15/201812. Net Loss Per ShareThree Months Ended    March 31,  ~  ~ ! Stock options outstanding  ~    ~ N[  Warrants outstanding  ~ )   ~ * % Convertible notes outstanding   -   ~ fX $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/*h~rf0:*=PF0*8X> @:    l  "  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Research and Development ExpensCash Flows (1)Item 6 Exhibits Subsidiaries of the RegistrantU } 1} $ }  } $ }  }  $ } } $ }  } $ "     ARGOS THERAPEUTICS INC 10-Q 05/15/2018f^Comparison of the Three Months Ended March 31, 2017 with the Three Months Ended March 31, 2018Three Months Ended ~    %    March 31,  ~  ~   Change  Change   (in thousands)   Revenue ~   ~ \  ~ [    *  Operating expenses                 Research and development~ {~ V  ~    (29.9 %)"General and administrative~ =~ '  ~  "  (36.9 %),$Impairment of property and equipment~  -  ~  V   *Restructuring costs~ BN -  ~  ±   *      Total operating expenses~ ~ }  ~    (81.8 %)     Loss from operations~ P~   ~  F  W@ %Interest income~ ~~ J  ~    (41.0 %)Interest expense~ ~   ~     79.6 %,$Gain on early extinguishment of debt~  -  ~     *1)Change in fair value of warrant liability~ >~ V  ~  B   * Other expense~ ~   ~     (274.0 %)     Net loss~ ‡~  ~  FW   91. 2 %$____________________________DlB6* . @!!          l  7  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three Months Cash Flows (1)Item 6 Exhibits Subsidiaries of the RegistrantU } 1} $ } $} $ } $} $                              ARGOS THERAPEUTICS INC 10-Q 05/15/2018)!Research and Development Expenses$Three Months Ended March 31,  ~  ~    (in thousands)/ 'Direct research and development expense          by program: Rocapuldencel-T ~ %  ~ 0 AGS-004~ ~ 6-%Total direct research and development~ n&~ 1program expense,$Commercial manufacturing development~ .~ expense1)Indirect research and development expense~ [~ %.&Total research and development expense~ {~ V$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/<sg[! q^Y=PF0*8X> @Z       l  8  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three Months !Research and Development ExpensItem 6 Exhibits Subsidiaries of the RegistrantU } 0} $ }  } $ } U} $                          ARGOS THERAPEUTICS INC 10-Q 05/15/2018 Cash FlowsThree Months Ended    March 31,  ~  ~    (in thousands)' Net cash (used in) provided by:         Operating activities ~ B  ~ ʪ Investing activities~ z~ Financing activities~ .~ m/'Effect of exchange rate changes on cash~ ~ 0(Net increase (decrease) in cash and cash~ ~  equivalents$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/4y~r<"=PF0*8X> @b        l  U@F  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three Months !Research and Development ExpensCash Flows (1) Subsidiaries of the RegistrantU } I } $ }  @ U     ARGOS THERAPEUTICS INC 10-Q 05/15/2018Item 6. ExhibitsExhibitDescription of Exhibit Number    @ - %Restated Certificate of Incorporation  / 'of the Registrant, as amended (filed as  . &Exhibit 3.1 to the Registrant?s Annual=5Report on Form 10-K on April 2, 2018 and incorporatedherein by reference)333333$@-%Amended and Restated Sales Agreement,2*dated February 2, 2018, by and between the4,Registrant and Cowen and Company, LLC (filed2*as Exhibit 1.1 to the Registrant?s Current2*Report on Form 8-K on February 5, 2018 and)!incorporated herein by reference) 10.2+4,Evaluation and Option Agreement for a Patent/'License, dated February 1, 2018, by and-%between the Registrant, Pharmstandard.&International S.A. and Actigen Limited3+(filed as Exhibit 10.49 to the Registrant?s3+Annual Report on Form 10-K on April 2, 2018-%and incorporated herein by reference)DT lxl+[\ o!j7 !"#$%&'()*+,-./0123456789:;<=>? 10.3+ - %Third Amendment to License Agreement,!!4!,dated March 23, 2018, between the Registrant""1")and Lummy (Hong Kong) Co., Ltd. (filed as##0#(Exhibit 10.51 to the Registrant?s Annual$$=$5Report on Form 10-K on April 2, 2018 and incorporated%%%herein by reference)&&& '10.4*'2'*Letter from the Registrant to Medinet Co.,((0((Ltd., dated February 14, 2018, regarding)).)&revocation of certain rights under the**-*%novated, amended and restated license+++ agreement,,, -21.1*-&-Subsidiaries of the Registrant... /31.1*/,/$Certification of principal executive00.0&officer pursuant to Rules 13a-14(a) or1101(15d-14(a) of the Securities Exchange Act22/2'of 1934, as adopted pursuant to Section33-3%302 of the Sarbanes-Oxley Act of 2002444 531.2*5,5$Certification of principal financial66.6&officer pursuant to Rules 13a-14(a) or7707(15d-14(a) of the Securities Exchange Act88/8'of 1934, as adopted pursuant to Section99-9%302 of the Sarbanes-Oxley Act of 2002::: ;32.1#;4;,Certifications pursuant to 18 U.S.C. Section<<0<(1350, as adopted pursuant to Section 906==1=)of The Sarbanes-Oxley Act of 2002, by the>>0>(Registrant?s principal executive officer??'?and principal financial officerD lbp8u+J&C>]O@ABCDEFGHIJKLMNOPQRST@@@A101.INSAAXBRL Instance DocumentBBBC101.SCHC/C'XBRL Taxonomy Extension Schema DocumentDDDE101.CALE4E,XBRL Taxonomy Extension Calculation LinkbaseFFFDocumentGGGH101.DEFH3H+XBRL Taxonomy Extension Definition LinkbaseIIIDocumentJJJK101.LABK.K&XBRL Taxonomy Extension Label LinkbaseLLLDocumentMMMN101.PREN,N$XBRL Taxonomy Extension PresentationOOOLinkbase DocumentPQ$R____________________________1S)Created by Morningstar Document Research.0T(http://documentresearch.morningstar.com/.w%~Zc7wO=PF0*8X> @TTSSRR l  z  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC No changesTABLE OF CONTENTS Balance SheetIncome StatementIncome Statement (1) Cash Flows!Recently Adopted Accounting Sta!Recently Adopted Accounting (1)!2 Fair Value of Financial Instr!2 Fair Value of Financial I (1)!2 Fair Value of Financial I (2)!2 Fair Value of Financial I (3)!2 Fair Value of Financial I (4)!4 Property and Equipment and As!6 Notes Payable and Gain on Ear!2014 Stock Incentive Plan and 2!2014 Stock Incentive Plan a (1)!Valuation Assumptions for Stock 9 Warrants9 Warrants (1)9 Warrants (2)12 Net Loss Per Share12 Net Loss Per Share (1)!Comparison of the Three Months !Research and Development ExpensCash Flows (1)Item 6 ExhibitsU } *} $ }       ARGOS THERAPEUTICS INC 10-Q 05/15/2018&Subsidiaries of the Registrant Name   Jurisdiction    DC Bio Corp.  Nova Scotia, Canada  +#Argos Therapeutics (Europe) S.?.r.lBertrange, Luxembourg$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.:vj^:o=PF0*8X> @ Root Entry FBook    !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~